Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
This meta-analysis aims to evaluate and compare the effectiveness and safety of pregabalin vs. gabapentin in managing neuropathic pain. Methods: This study followed PRISMA guidelines and employed the PICOS search strategy. The Spotlight series continues with this article on gabapentin and pregabalin, collectively known as gabapentinoids. They are anticonvulsant medicines but also have analgesic and anxiolytic actions. 1 This article focuses on the use of gabapentinoids for neuropathic pain. Background Few direct head-to-head comparisons have been conducted between drugs for the treatment of diabetic peripheral neuropathic pain (DPNP). Approved or recommended drugs in this indication include duloxetine (DLX), pregabalin (PGB), gabapentin (GBP) and amitriptyline (AMT). We conducted an indirect meta-analysis to compare the efficacy and tolerability of DLX with PGB and GBP in DPNP Pregabalin (PGB) and gabapentin (GBP) are recommended as the first-line treatment for neuropathic pain due to SCI [18, 19]. Both drugs have been shown to be effective in the treatment of neuropathic pain due to postherpetic neuralgia [20 – 26] and diabetic peripheral neuropathy [24 – 29]. Pregabalin is licensed for peripheral and central neuropathic pain whereas gabapentin is licensed for peripheral neuropathic pain only. Use of gabapentin for central neuropathic pain is therefore off-label. A few studies have found that pregabalin has fewer side effects and may be more efficacious for neuropathic pain than gabapentin. Several studies reviewing conversion of gabapentin to pregabalin predict that a rough ratio for conversion is about 6:1 gabapentin to pregabalin. Gabapentin and pregabalin are often considered first line treatment options for various neuropathic pain conditions. The purpose of this retrospective cohort study was to compare clinically meaningful pain reduction and other relevant outcomes among patients prescribed either gabapentin or pregabali Gabapentin and pregabalin are FDA-approved to treat some of the same conditions, including postherpetic neuralgia in adults. Both drugs are also indicated to treat partial seizures in adults and certain children with epilepsy (a seizure disorder) when taken along with other medication. The Neuropathic Pain Special Interest Group (NeuPSIG) has recommended antiepileptic drugs to manage neuropathic pain [].Accordingly, the United States (US) Food and Drug Administration (FDA) has permitted gabapentin treatment for postherpetic neuralgia, while pregabalin is approved for postherpetic neuralgia, neuropathic pain associated with diabetes or spinal cord injury, and fibromyalgia []. However, there is a lack of clarity regarding their comparative efficacy and safety. This meta-analysis aims to evaluate and compare the effectiveness and safety of pregabalin vs. gabapentin in managing neuropathic pain. Methods: This study followed PRISMA guidelines and employed the PICOS search strategy. Comparative studies (clinical trials What are pregabalin and gabapentin? Pregabalin and gabapentin, collectively gabapentinoids, are primarily anticonvulsant drugs. Over the past decade, they have been increasingly prescribed for pain. 1 They are recommended for neuropathic pain in adults 2 3 (table 1), but are commonly used off-label for other pain disorders such as low back pain, sciatica, and migraine. 9 10 Pregabalin was one Recent meta-analyses comparing gabapentin and pregabalin in the treatment of various neuropathic pain conditions have shown superior pain control with pregabalin. A Cochrane review from 2015 demonstrated a comparable number needed to treat (NNT) for a 50% reduction in pain intensity for both medications, independent of the etiology of pain. LAS VEGAS — Patients with neuropathic pain are more likely to achieve effective therapeutic dose when treated with pregabalin compared with gabapentin, and gabapentin was found to often be The evidence for use in non-neuropathic pain and other off-label indications is poor. 3 Despite the paucity of evidence, off-label prescriptions in primary care have continued to escalate and accounted for 52.0% of gabapentin and 54.8% of pregabalin prescriptions with an identified indication in 2017. 2 Of these, non-neuropathic pain accounted Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care. 2012;29:177–182. doi: 10.1177/1049909111412539. [Google Scholar] 19. We would like to show you a description here but the site won’t allow us. Based on the few studies examined, both drugs improve neuropathic pain but there is no clear difference between the two when it comes to pain reduction. However, pregabalin seems to result in quicker pain relief than gabapentin, which may be advantageous. Ghosh et al.9. Yılmaz B, Yaşar E, Köroğlu Omaç Ö, et al. Gabapentin vs. pregabalin for the treatment of neuropathic pain in patients with spinal cord injury: a crossover study. Turk J Phys Med Rehab. 2015;61:1–5. doi: 10.5152/tftrd.2015.79069. [Google Scholar] 69. Pregabalin demonstrates superior efficacy and safety compared with gabapentin in treating neuropathic pain, with improved pain control, quality of life, and fewer adverse events, The study compared the effectiveness and safety of pregabalin and gabapentin in neuropathic pain management. Pregabalin showed significantly better results than gabapentin in terms of pain reduction, as measured by the Visual Analog Scale (VAS).
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |